Tumor-Derived IL33 Promotes Tissue-Resident CD8 + T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy

• Published in: Cancer immunology research Vol. 8; no. 11; p. 1381
• Main Authors: Chen, Lujun, Sun, Runzi, Xu, Junchi, Zhai, Wensi, Zhang, Dachuan, Yang, Min, Yue, Cuihua, Chen, Yichao, Li, Song, Turnquist, Heth, Jiang, Jingting, Lu, Binfeng
• Format: Journal Article
• Language: English
• Published: United States 01.11.2020
• Subjects: Animals; CD8-Positive T-Lymphocytes - immunology; Disease Models, Animal; Humans; Immunotherapy - methods; Interleukin-33 - metabolism; Mice

Immune checkpoint blockade (ICB) immunotherapy has revolutionized cancer treatment by prolonging overall survival of patients with cancer. Despite advances in the clinical setting, the immune cellular network in the tumor microenvironment (TME) that mediates such therapy is not well understood. IL33...